Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming

Author(s):  
Mithun Khattar ◽  
Keli Song ◽  
Stephen Grossman ◽  
Kristina Xega ◽  
Xingyue He ◽  
...  
2017 ◽  
Vol 1 (9) ◽  
pp. 557-568 ◽  
Author(s):  
Maria Dolores Lopez Robles ◽  
Annaick Pallier ◽  
Virginie Huchet ◽  
Laetitia Le Texier ◽  
Severine Remy ◽  
...  

Key PointsCLEC-1 is restricted to CD16− myeloid DCs in human blood and acts as an inhibitory receptor to restrain downstream Th17 activation. CLEC-1–deficient rats highlight an in vivo function for CLEC-1 in preventing excessive T-cell priming and effector Th responses.


2007 ◽  
Vol 104 (39) ◽  
pp. 15460-15465 ◽  
Author(s):  
R. Obst ◽  
H.-M. van Santen ◽  
R. Melamed ◽  
A. O. Kamphorst ◽  
C. Benoist ◽  
...  

Biomaterials ◽  
2012 ◽  
Vol 33 (26) ◽  
pp. 6211-6219 ◽  
Author(s):  
Evan A. Scott ◽  
Armando Stano ◽  
Morgane Gillard ◽  
Alexandra C. Maio-Liu ◽  
Melody A. Swartz ◽  
...  

2015 ◽  
Vol 9 (1) ◽  
pp. 24-37 ◽  
Author(s):  
S M Dillon ◽  
E J Lee ◽  
C V Kotter ◽  
G L Austin ◽  
S Gianella ◽  
...  

2020 ◽  
Vol Volume 15 ◽  
pp. 6579-6592
Author(s):  
Ross Darling ◽  
Sujata Senapati ◽  
John Christiansen ◽  
Luman Liu ◽  
Amanda E Ramer-Tait ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document